Eyepoint Pharmaceuticals (EYPT) Competitors $10.06 +0.22 (+2.24%) Closing price 04:00 PM EasternExtended Trading$10.14 +0.08 (+0.84%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. TXG, TRNS, ALNT, LAB, CTKB, AEHR, QSI, QTRX, SENS, and MASSShould you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Eyepoint Pharmaceuticals vs. Its Competitors 10x Genomics Transcat Allient Standard BioTools Cytek Biosciences Aehr Test Systems Quantum-Si Quanterix Senseonics 908 Devices 10x Genomics (NASDAQ:TXG) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Does the media favor TXG or EYPT? In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than 10x Genomics. MarketBeat recorded 5 mentions for Eyepoint Pharmaceuticals and 4 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.70 beat Eyepoint Pharmaceuticals' score of 0.44 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in TXG or EYPT? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is TXG or EYPT more profitable? 10x Genomics has a net margin of -25.14% compared to Eyepoint Pharmaceuticals' net margin of -261.91%. 10x Genomics' return on equity of -23.22% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Eyepoint Pharmaceuticals -261.91%-54.27%-41.75% Which has better valuation & earnings, TXG or EYPT? Eyepoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.49-$182.63M-$1.30-9.52Eyepoint Pharmaceuticals$43.27M16.00-$130.87M-$2.41-4.17 Do analysts rate TXG or EYPT? 10x Genomics presently has a consensus target price of $14.13, suggesting a potential upside of 14.19%. Eyepoint Pharmaceuticals has a consensus target price of $25.67, suggesting a potential upside of 155.14%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.46Eyepoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, TXG or EYPT? 10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Summary10x Genomics and Eyepoint Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$677.10M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio-4.1720.3628.1519.68Price / Sales16.00304.13438.32100.43Price / CashN/A42.3835.5357.53Price / Book2.047.768.235.67Net Income-$130.87M-$55.11M$3.23B$257.51M7 Day Performance-8.21%0.95%-0.01%0.52%1 Month Performance13.03%8.44%5.61%8.84%1 Year Performance-4.55%-2.38%26.52%14.18% Eyepoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyepoint Pharmaceuticals1.5928 of 5 stars$10.06+2.2%$25.67+155.1%-6.6%$677.10M$43.27M-4.17120TXG10x Genomics4.4511 of 5 stars$11.92-8.4%$14.96+25.5%-29.4%$1.60B$610.78M-9.171,240TRNSTranscat2.9062 of 5 stars$86.35-3.9%$114.00+32.0%-36.9%$837.47M$278.42M55.351,245ALNTAllient2.2429 of 5 stars$37.89-2.2%$31.00-18.2%+44.4%$656.16M$529.97M28.292,525LABStandard BioTools3.8037 of 5 stars$1.28-5.2%$2.50+95.3%-42.2%$512.76M$174.43M0.00620Positive NewsCTKBCytek Biosciences3.0446 of 5 stars$3.40-9.6%$5.60+64.7%-48.7%$476.24M$200.45M0.00500News CoverageAEHRAehr Test Systems3.4361 of 5 stars$14.82-5.0%$25.00+68.7%-14.5%$464.43M$66.22M19.0090Gap DownQSIQuantum-Si1.8737 of 5 stars$1.83-14.5%$3.48+89.9%+59.3%$392.69M$3.06M0.00150QTRXQuanterix2.5621 of 5 stars$6.30-9.7%$15.60+147.6%-63.6%$348.68M$137.42M-4.85460SENSSenseonics1.996 of 5 stars$0.49-2.6%$1.55+216.8%+11.3%$320.11M$23.68M-3.7690News CoverageAnalyst ForecastAnalyst RevisionGap UpMASS908 Devices1.1181 of 5 stars$6.41-3.6%$5.33-16.8%+17.5%$238.48M$59.63M-11.8760Positive News Related Companies and Tools Related Companies TXG Alternatives TRNS Alternatives ALNT Alternatives LAB Alternatives CTKB Alternatives AEHR Alternatives QSI Alternatives QTRX Alternatives SENS Alternatives MASS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts